Tue, 06 Oct 2026 07:30:00 -0400 · 10 days ago BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
2026-09-14T11:35:52.000Z · 4 weeks ago BriaCell announces DSMB recommendation to continue Bria-ABC study
Mon, 14 Sep 2026 07:30:00 -0400 · 4 weeks ago Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study
Tue, 08 Sep 2026 07:30:00 -0400 · 5 weeks ago BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
2026-08-24T11:35:06.000Z · 7 weeks ago BriaCell advances melanoma immunotherapy vaccine candidate Bria-MEL+
Mon, 24 Aug 2026 07:30:00 -0400 · 7 weeks ago BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
2026-08-05T13:46:04.000Z · 2 months ago BriaCell gets FDA clearance for Bria-PROS+ study in prostate cancer
Wed, 05 Aug 2026 07:30:00 -0400 · 2 months ago BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
Thu, 16 Jul 2026 07:30:00 -0400 · 3 months ago BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
2026-07-15T12:10:22.000Z · 3 months ago BriaCell arranges scalable manufacturing with Fujifilm Biotechnologies
Wed, 15 Jul 2026 07:30:00 -0400 · 3 months ago BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
Tue, 07 Jul 2026 07:30:00 -0400 · 3 months ago BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
Thu, 25 Jun 2026 07:30:00 -0400 · 3 months ago BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
2026-05-26T13:05:39.000Z · 4 months ago BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study
Tue, 26 May 2026 07:30:00 -0400 · 4 months ago BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
Fri, 22 May 2026 07:30:00 -0400 · 4 months ago BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
Fri, 15 May 2026 07:30:00 -0400 · 5 months ago BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
Thu, 14 May 2026 07:30:00 -0400 · 5 months ago BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
2026-05-13T14:41:55.000Z · 5 months ago BriaCell adds Penn Medicine as Phase 3 breast cancer study site
Wed, 13 May 2026 07:30:00 -0400 · 5 months ago BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
Tue, 12 May 2026 07:30:00 -0400 · 5 months ago BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
Thu, 07 May 2026 07:30:00 -0400 · 5 months ago BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
Wed, 06 May 2026 07:30:00 -0400 · 5 months ago BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
Mon, 27 Apr 2026 07:30:00 -0400 · 5 months ago BriaCell Announces Six Clinical Data Presentations at ASCO 2026
Tue, 21 Apr 2026 07:30:00 -0400 · 5 months ago BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
2026-04-20T11:41:56.000Z · 5 months ago BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR
Mon, 20 Apr 2026 07:30:00 -0400 · 5 months ago BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
Tue, 31 Mar 2026 16:05:00 -0400 · 6 months ago BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
Mar 18, 2026, 7:30 AM EDT · 7 months ago BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference
Mar 10, 2026, 7:30 AM EDT · 7 months ago BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
Mar 5, 2026, 4:04 PM EST · 7 months ago BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
2026-02-18T22:35:25.000Z · 8 months ago BriaPro to purchase BriaCell’s license to develop, commercialize sCD80
Feb 18, 2026, 5:30 PM EST · 8 months ago BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
2026-02-17T12:40:59.000Z · 8 months ago BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study
2026-01-28T12:40:40.000Z · 8 months ago BriaCell says patient images show regression, resolution of metastsized tumors
Jan 28, 2026, 7:30 AM EST · 8 months ago BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
2026-01-27T12:41:04.000Z · 8 months ago BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer
Jan 27, 2026, 7:30 AM EST · 8 months ago BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
Jan 15, 2026, 4:05 PM EST · 9 months ago BriaCell Therapeutics Announces Closing of US$30 million Public Offering
Jan 13, 2026, 9:00 PM EST · 9 months ago BriaCell Therapeutics Announces Pricing of $30 million Public Offering
2026-01-13T14:35:29.000Z · 9 months ago BriaCell Therapeutics trading halted, volatility trading pause
Jan 13, 2026, 7:30 AM EST · 9 months ago BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient
Dec 18, 2025, 7:30 AM EST · 10 months ago “Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
Dec 10, 2025, 7:30 AM EST · 10 months ago BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
Dec 9, 2025, 7:30 AM EST · 10 months ago BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
Dec 2, 2025, 7:30 AM EST · 10 months ago BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025
Nov 25, 2025, 7:30 AM EST · 10 months ago BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025
Nov 20, 2025, 7:30 AM EST · 11 months ago BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics
Nov 18, 2025, 7:30 AM EST · 11 months ago BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025
Nov 7, 2025, 7:30 AM EST · 11 months ago BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025
Nov 4, 2025, 7:30 AM EST · 11 months ago BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models
Oct 21, 2025, 7:50 AM EDT · 12 months ago BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
Oct 21, 2025, 7:30 AM EDT · 12 months ago BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
Oct 20, 2025, 7:30 AM EDT · 12 months ago BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025
Oct 13, 2025, 7:30 AM EDT · 1 year ago BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025
Oct 3, 2025, 7:30 AM EDT · 1 year ago BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting
Aug 26, 2025, 7:30 AM EDT · 1 year ago BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal
Aug 25, 2025, 7:30 AM EDT · 1 year ago BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer
Aug 21, 2025, 12:00 PM EDT · 1 year ago BriaCell Announces Proposed Effective Date of Share Consolidation